Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis

FEMS Immunology and Medical Microbiology

Volumn 63, Issue 1, 2011, Pages 1-9

  da Silva, Pedro Eduardo Almeida ^a   von Groll, Andrea ^a,b   Martin, Anandi ^b   Palomino, Juan Carlos ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

ATP binding cassette; Drug resistance; Efflux; Pumps; Transporters; Tuberculosis

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENOME; BACTERIAL VIRULENCE; BIOINFORMATICS; DISEASE CONTROL; EUKARYOTIC CELL; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENOME SIZE; HUMAN; MOLECULAR MECHANICS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROKARYOTIC CELL; SHORT SURVEY; TRANSCRIPTION REGULATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG RESISTANCE, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MYCOBACTERIUM TUBERCULOSIS;

EID: 80052580674     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00831.x     Document Type: Short Survey

References (95)

1. Aeschlimann JR, Dresser LD, Kaatz GW & Rybak MJ (1999) Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Ch43: 335-340.
2. Aínsa JA, Blokpoel MC, Otal I, Young DB, De Smet KA & Martín C (1998) Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol180: 5836-5843.
3. Amaral L, Martins M, Viveiros M, Molnar J & Kristiansen JE (2008) Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets9: 816-819.
4. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM & Pastan I (1992) Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. P Natl Acad Sci USA 89: 8472-8476.
5. Ambudkar SV, Dey S, Hrycyna CA & Cardarelli C (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol39: 361-398.
6. Balganesh M, Kuruppath S, Marcel N, Sharma S, Nair A & Sharma U (2010) Rv1218c, an ABC Transporter of Mycobacterium tuberculosis with Implications in Drug Discovery. Antimicrob Agents Ch54: 5167-5172.
7. Bellinzoni M, Buroni S, Schaeffer F, Riccardi G, De Rossi E & Alzari PM (2009) Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator. J Bacteriol191: 7531-7537.
8. Bigi F, Gioffre A, Klepp Let al. (2004) The knockout of the lprG-Rv1410 operon produces strong attenuation of Mycobacterium tuberculosis. Microbes Infect6: 182-187.
9. Bina XR, Philippart JA & Bina JE (2009) Effect of the efflux inhibitors 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide on antimicrobial susceptibility and virulence factor production in Vibrio cholerae. J Antimicrob Chemoth63: 103-108.
10. Bonilla CA, Crossa A, Jave HOet al. (2008) Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 3: e2957.
11. Borst P, Zelcer N & van Helvoort A (2000) ABC transporters in lipid transport. Biochim Biophys Acta1486: 128-144.
12. Braibant M, Gilot P & Content J (2000) The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev24: 449-467.
13. Buroni S, Manina G, Guglierame P, Pasca MR, Riccardi G & De Rossi E (2006) LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis. Antimicrob Agents Ch50: 4044-4052.
14. Cattoir V (2004) Efflux-mediated antibiotics resistance in bacteria. Pathol Biol52: 607-616.
15. Chan YY & Chua KL (2010) Growth-related changes in intracellular spermidine and its effect on efflux pump expression and quorum sensing in Burkholderia pseudomallei. Microbiology156: 1144-1154.
16. Choudhuri BS, Bhakta S, Barik R, Basu J, Kundu M & Chakrabarti P (2002) Overexpression and functional characterization of an ABC (ATP-binding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem J367: 279-285.
17. Cohen SP, Levy SB, Foulds J & Rosner JL (1993) Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. J Bacteriol 175: 7856-7862.
18. Colangeli R, Helb D, Sridharan Set al. (2005) Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol55: 1829-1840.
19. Danilchanka O, Mailaender C & Niederweis M (2008) Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob Agents Ch52: 2503-2511.
20. De Rossi E, Blokpoel MC, Cantoni R, Branzoni M, Riccardi G, Young DB, De Smet KA & Ciferri O (1998a) Molecular cloning and functional analysis of a novel tetracycline resistance determinant, tet(V), from Mycobacterium smegmatis. Antimicrob Agents Ch42: 1931-1937.
21. De Rossi E, Branzoni M, Cantoni R, Milano A, Riccardi G & Ciferri O (1998b) mmr, a Mycobacterium tuberculosis gene conferring resistance to small cationic dyes and inhibitors. J Bacteriol180: 6068-6071.
22. De Rossi E, Arrigo P, Bellinzoni M, Silva PA, Martín C, Aínsa JA, Guglierame P & Riccardi G (2002) The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med8: 714-724.
23. De Rossi E, Ainsa JA & Riccardi G (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 30: 36-52.
24. Domenech P, Kobayashi H, LeVier K, Walker GC & Barry CE (2009) BacA, an ABC transporter involved in maintenance of chronic murine infections with Mycobacterium tuberculosis. J Bacteriol191: 477-485.
25. Dutta NK, Mehra S & Kaushal D (2010) A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One5: e10069.
26. Dye C (2009) Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol7: 81-87.
27. Escribano I, Rodriguez JC, Llorca B, García-Pachon E, Ruiz M & Royo G (2007) Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy53: 397-401.
28. Farrow MF & Rubin EJ (2008) Function of a mycobacterial major facilitator superfamily pump requires a membrane-associated lipoprotein. J Bacteriol190: 1783-1791.
29. Fontán PA, Voskuil MI, Gomez M, Tan D, Pardini M, Manganelli R, Fattorini L, Schoolnik GK & Smith I (2009) The Mycobacterium tuberculosis sigma factor sigmaB is required for full response to cell envelope stress and hypoxia in vitro, but it is dispensable for in vivo growth. J Bacteriol191: 5628-5633.
30. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J & Friedland G (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet368: 1575-1580.
31. Geiman DE, Raghunand TR, Agarwal N & Bishai WR (2006) Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Ch50: 2836-2841.
32. Guilfoile PG & Hutchinson CR (1991) A bacterial analog of the mdr gene of mammalian tumor cells is present in Streptomyces peucetius, the producer of daunorubicin and doxorubicin. P Natl Acad Sci USA88: 8553-8557.
33. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, Venkatesan K & Sharma VD (2010a) Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist16: 21-28.
34. Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, Sharma VD, Tyagi AK & Katoch VM (2010b) jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian J Med Res132: 176-188.
35. Høiby N, Ciofu O & Bjarnsholt T (2010) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol5: 1663-1674.
36. Jarlier V & Nikaido H (1994) Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 123: 11-18.
37. Jiang X, Zhang W, Zhang Y, Gao F, Lu C, Zhang X & Wang H (2008) Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb Drug Resist14: 7-11.
38. Kaatz GW (2002) Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance. Expert Opin Emerg Drugs 7: 223-233.
39. Kaatz GW (2005) Bacterial efflux pump inhibition. Curr Opin Investig D6: 191-198.
40. Kim SY, Shin SJ, Song CH, Jo EK, Kim HJ & Park JK (2008) Identification of novel metronidazole-inducible genes in Mycobacterium smegmatis using a customized amplification library. FEMS Microbiol Lett282: 282-289.
41. Klyachko KA & Neyfakh AA (1998) Paradoxical enhancement of the activity of a bacterial multidrug transporter caused by substitutions of a conserved residue. J Bacteriol180: 2817-2821.
42. Levy SB (1992) Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Ch36: 695-703.
43. Li XZ & Nikaido H (2004) Efflux-mediated drug resistance in bacteria. Drugs64: 159-204.
44. Li XZ & Nikaido H (2009) Efflux-mediated drug resistance in bacteria: an update. Drugs 69: 1555-1623.
45. Li XZ, Poole K & Nikaido H (2003) Contributions of MexAB-OprM and an EmrE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob Agents Ch47: 27-33.
46. Li XZ, Zhang L & Nikaido H (2004) Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Ch48: 2415-2423.
47. Liu J, Takiff HE & Nikaido H (1996) Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol178: 3791-3795.
48. Lomovskaya O & Bostian KA (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol71: 910-918.
49. Lomovskaya O, Warren MS, Lee Aet al. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Ch 45: 105-116.
50. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD & Victor TC (2009) A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Ch 53: 3181-3189.
51. Louw GE, Warren RM, Gey van Pittius NCet al. (2011) Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobacterium tuberculosis through efflux. Am J Resp Crit Care, DOI:10.1164/rccm.201011-1924OC.
52. Martins M, Santos B, Martins A, Viveiros M, Couto I, Cruz A, Pages JM, Molnar J, Fanning S & Amaral L (2006) An instrument-free method for the demonstration of efflux pump activity of bacteria. In Vivo20: 657-664.
53. McDermott PF, White DG, Podglajen I, Alekshun MN & Levy SB (1998) Multidrug resistance following expression of the Escherichia coli marA gene in Mycobacterium smegmatis. J Bacteriol180: 2995-2998.
54. McMurry L, Petrucci RE & Levy SB (1980) Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. P Natl Acad Sci USA77: 3974-3977.
55. Migliori GB, Loddenkemper R, Blasi F & Raviglione MC (2007) 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? Eur Respir J 29: 423-427.
56. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL, Manganelli R & Riccardi G (2009) Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis89: 84-90.
57. Morris RP, Nguyen L, Gatfield Jet al. (2005) Ancestral antibiotic resistance in Mycobacterium tuberculosis. P Natl Acad Sci USA102: 12200-12205.
58. Nikaido H (1998) Multiple antibiotic resistance and efflux. Curr Opin Microbiol1: 516-523.
59. Nikaido H & Zgurskaya HI (1999) Antibiotic efflux mechanisms. Curr Opin Infect Dis12: 529-536.
60. Nomura K, Ogawa M, Miyamoto H, Muratani T & Taniguchi H (2004) Antibiotic susceptibility of glutaraldehyde-tolerant Mycobacterium chelonae from bronchoscope washing machines. Am J Infect Control32: 185-188.
61. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J & Amaral L (2003) Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Ch47: 917-922.
62. Palomino JC, Fernandes-Ramos D & Almeida da Silva P (2009) New anti-tuberculosis drugs: strategies, sources and new molecules. Curr Med Chem 16: 1898-1904.
63. Parent MA, Goenka R, Murphy E, LeVier K, Carreiro N, Golding B, Ferguson G, Roop RM, Walker GC & Baldwin CL (2007) Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes Infect9: 55-62.
64. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E & Riccardi G (2004) Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Ch48: 3175-3178.
65. Pasca MR, Guglierame P, De Rossi E, Zara F & Riccardi G (2005) mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis. Antimicrob Agents Ch49: 4775-4777.
66. Paulsen IT & Lewis K (2001) Microbial multidrug efflux: introduction. J Mol Microb Biotech 3: 143-144.
67. Paulsen IT, Chen J, Nelson KE & Saier MH Jr (2001) Comparative genomics of microbial drug efflux systems. J Mol Microb Biotech3: 145-150.
68. Pethe K, Swenson DL, Alonso S, Anderson J, Wang C & Russell DG (2004) Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. P Natl Acad Sci USA101: 13642-13647.
69. Piddock LJ (2006a) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev19: 382-402.
70. Piddock LJ (2006b) Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol4: 629-636.
71. Putman M, van Veen HW & Konings WN (2000) Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol R64: 672-693.
72. Ramaswamy S & Musser JM (1998) Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79: 3-29.
73. Ramon-Garcia S, Martin C, Ainsa JA & De Rossi E (2006) Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemoth57: 252-259.
74. Ramon-Garcia S, Martin C, De Rossi E & Aínsa JA (2007) Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. J Antimicrob Chemoth59: 544-547.
75. Ramón-García S, Martín C, Thompson CJ & Aínsa JA (2009) Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Ch53: 3675-3682.
76. Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, Kern WV & Amaral L (2008) Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemoth61: 1076-1082.
77. Saier MH Jr, Yen MR, Noto K, Tamang DG & Elkan C (2009) The transporter classification database: recent advances. Nucleic Acids Res 37: D274-D278.
78. Sander P, De Rossi E, Boddinghaus B, Cantoni R, Branzoni M, Bottger EC, Takiff H, Rodriquez R, Lopez G & Riccardi G (2000) Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol Lett193: 19-23.
79. Schaller A, Sun Z, Yang Y, Somoskovi A & Zhang Y (2002) Salicylate reduces susceptibility of Mycobacterium tuberculosis to multiple antituberculosis drugs. Antimicrob Agents Ch46: 2636-2639.
80. Sharma S, Kumar M, Sharma S, Nargotra A, Koul S & Khan IA (2010) Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemoth65: 1694-1701.
81. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM & Hasnain SE (2004) Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection32: 109-111.
82. Silva PE, Bigi F, Santangelo MP, Romano MI, Martín C, Cataldi A & Aínsa JA (2001) Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Ch45: 800-804.
83. Spies FS, da Silva PE, Ribeiro MO, Rossetti ML & Zaha A (2008) Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Ch52: 2947-2949.
84. Takiff HE, Cimino M, Musso MC, Weisbrod T, Martinez R, Delgado MB, Salazar L, Bloom BR & Jacobs WRJr (1996) Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. P Natl Acad Sci USA93: 362-366.
85. Tseng TT, Gratwick KS, Kollman J, Park D, Nies DH, Goffeau A & Saier MHJr (1999) J Mol Microb Biotech1: 107-125.
86. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J & Boeree MJ (2010) The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One5: e12640.
87. Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, Ordway D & Amaral L (2002) Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Ch46: 2804-2810.
88. Viveiros M, Martins M, Couto I, Rodrigues L, Spengler G, Martins A, Kristiansen JE, Molnar J & Amaral L (2008) New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. Curr Drug Targets9: 760-778.
89. Webber MA & Piddock LJ (2003) The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemoth51: 9-11.
90. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO & Schoolnik GK (1999) Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. P Natl Acad Sci USA96: 12833-12838.
91. World Health Organization (1997) Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. Geneva, World Health Organization, 1997 (WHO/TB/97.229).
92. World Health Organization (2010a) Treatment of Tuberculosis Guidelines, WHO/HTM/TB/2009.420, 4th edn. WHO, Geneva.
93. World Health Organization (2010b) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 2010. WHO/HTM/TB/2010.3.
94. Yamada H, Kurose-Hamada S, Fukuda Y, Mitsuyama J, Takahata M, Minami S, Watanabe Y & Narita H (1997) Quinolone susceptibility of norA-disrupted Staphylococcus aureus. Antimicrob Agents Ch41: 2308-2309.
95. Zhang Y & Telenti A (2000) Genetics of drug resistance in Mycobacterium tuberculosis. Molecular Genetics of Mycobacteria (Hatfull GF & Jacobs WR, ed), pp. 235-254. ASM, Washington, DC.